Cargando…

Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study

Several clinical trials have demonstrated that many SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) can reduce the risk of cardiovascular events in patients with Type 2 diabetes and atherosclerotic cardiovascular disease. Recent reports indicate an underutilization of new cardiomet...

Descripción completa

Detalles Bibliográficos
Autores principales: Dzaye, Omar, Berning, Philipp, Razavi, Alexander C., Adhikari, Rishav, Jha, Kunal, Nasir, Khurram, Ayers, John W., Mortensen, Martin Bødtker, Blaha, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372305/
https://www.ncbi.nlm.nih.gov/pubmed/35966558
http://dx.doi.org/10.3389/fcvm.2022.936651
_version_ 1784767352083054592
author Dzaye, Omar
Berning, Philipp
Razavi, Alexander C.
Adhikari, Rishav
Jha, Kunal
Nasir, Khurram
Ayers, John W.
Mortensen, Martin Bødtker
Blaha, Michael J.
author_facet Dzaye, Omar
Berning, Philipp
Razavi, Alexander C.
Adhikari, Rishav
Jha, Kunal
Nasir, Khurram
Ayers, John W.
Mortensen, Martin Bødtker
Blaha, Michael J.
author_sort Dzaye, Omar
collection PubMed
description Several clinical trials have demonstrated that many SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) can reduce the risk of cardiovascular events in patients with Type 2 diabetes and atherosclerotic cardiovascular disease. Recent reports indicate an underutilization of new cardiometabolic drugs, including SGLT2i and GLP-1 RA. We aimed to evaluate the use of online search volumes to reflect United States prescription rates. A repeated cross-sectional analysis of Google search volumes and corresponding data from the IQVIA National Prescription Audit (NPA) of pharmacy dispensing of newly prescribed drugs was performed. Monthly data for online searches and prescription between January 1, 2016 and December 31, 2021 were collected for selected SGLT2i and GLP-1 RA. Prescription data for drugs classes (SGLT2i and GLP-1 RA) and individual drugs were calculated as the total of queried data for branded drug names. Trends were analyzed for visual and quantitative correlation as well as predictive patterns. Overall, online searches increased by 157.6% (95% CI: 142.2–173.1%) and 295.2% (95% CI: 257.7–332.6%) for SGLT2i and GLP-1RA between 2016 and 2021. Prescription rates raised by 114.6% (95% CI: 110.8–118.4%) and 221.0% (95% CI: 212.1–229.9%) for SGLT2i and GLP-1RA for this period. Correlation coefficients (range 0.86–0.99) were strongest for drugs with growing number of prescriptions, for example dapagliflozin, empagliflozin, ertugliflozin, dulaglutide, and semaglutide. Online searches might represent an additional tool to monitor the utilization trends of cardiometabolic drugs. Associations were strongest for drugs with reported cardioprotective effect. Thus, trends in online searches complement conventionally acquired data to reflect and forecast prescription trends of cardiometabolic drugs.
format Online
Article
Text
id pubmed-9372305
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93723052022-08-13 Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study Dzaye, Omar Berning, Philipp Razavi, Alexander C. Adhikari, Rishav Jha, Kunal Nasir, Khurram Ayers, John W. Mortensen, Martin Bødtker Blaha, Michael J. Front Cardiovasc Med Cardiovascular Medicine Several clinical trials have demonstrated that many SGLT-2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) can reduce the risk of cardiovascular events in patients with Type 2 diabetes and atherosclerotic cardiovascular disease. Recent reports indicate an underutilization of new cardiometabolic drugs, including SGLT2i and GLP-1 RA. We aimed to evaluate the use of online search volumes to reflect United States prescription rates. A repeated cross-sectional analysis of Google search volumes and corresponding data from the IQVIA National Prescription Audit (NPA) of pharmacy dispensing of newly prescribed drugs was performed. Monthly data for online searches and prescription between January 1, 2016 and December 31, 2021 were collected for selected SGLT2i and GLP-1 RA. Prescription data for drugs classes (SGLT2i and GLP-1 RA) and individual drugs were calculated as the total of queried data for branded drug names. Trends were analyzed for visual and quantitative correlation as well as predictive patterns. Overall, online searches increased by 157.6% (95% CI: 142.2–173.1%) and 295.2% (95% CI: 257.7–332.6%) for SGLT2i and GLP-1RA between 2016 and 2021. Prescription rates raised by 114.6% (95% CI: 110.8–118.4%) and 221.0% (95% CI: 212.1–229.9%) for SGLT2i and GLP-1RA for this period. Correlation coefficients (range 0.86–0.99) were strongest for drugs with growing number of prescriptions, for example dapagliflozin, empagliflozin, ertugliflozin, dulaglutide, and semaglutide. Online searches might represent an additional tool to monitor the utilization trends of cardiometabolic drugs. Associations were strongest for drugs with reported cardioprotective effect. Thus, trends in online searches complement conventionally acquired data to reflect and forecast prescription trends of cardiometabolic drugs. Frontiers Media S.A. 2022-07-29 /pmc/articles/PMC9372305/ /pubmed/35966558 http://dx.doi.org/10.3389/fcvm.2022.936651 Text en Copyright © 2022 Dzaye, Berning, Razavi, Adhikari, Jha, Nasir, Ayers, Mortensen and Blaha. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Dzaye, Omar
Berning, Philipp
Razavi, Alexander C.
Adhikari, Rishav
Jha, Kunal
Nasir, Khurram
Ayers, John W.
Mortensen, Martin Bødtker
Blaha, Michael J.
Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
title Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
title_full Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
title_fullStr Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
title_full_unstemmed Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
title_short Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
title_sort online searches for sglt-2 inhibitors and glp-1 receptor agonists correlate with prescription rates in the united states: an infodemiological study
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372305/
https://www.ncbi.nlm.nih.gov/pubmed/35966558
http://dx.doi.org/10.3389/fcvm.2022.936651
work_keys_str_mv AT dzayeomar onlinesearchesforsglt2inhibitorsandglp1receptoragonistscorrelatewithprescriptionratesintheunitedstatesaninfodemiologicalstudy
AT berningphilipp onlinesearchesforsglt2inhibitorsandglp1receptoragonistscorrelatewithprescriptionratesintheunitedstatesaninfodemiologicalstudy
AT razavialexanderc onlinesearchesforsglt2inhibitorsandglp1receptoragonistscorrelatewithprescriptionratesintheunitedstatesaninfodemiologicalstudy
AT adhikaririshav onlinesearchesforsglt2inhibitorsandglp1receptoragonistscorrelatewithprescriptionratesintheunitedstatesaninfodemiologicalstudy
AT jhakunal onlinesearchesforsglt2inhibitorsandglp1receptoragonistscorrelatewithprescriptionratesintheunitedstatesaninfodemiologicalstudy
AT nasirkhurram onlinesearchesforsglt2inhibitorsandglp1receptoragonistscorrelatewithprescriptionratesintheunitedstatesaninfodemiologicalstudy
AT ayersjohnw onlinesearchesforsglt2inhibitorsandglp1receptoragonistscorrelatewithprescriptionratesintheunitedstatesaninfodemiologicalstudy
AT mortensenmartinbødtker onlinesearchesforsglt2inhibitorsandglp1receptoragonistscorrelatewithprescriptionratesintheunitedstatesaninfodemiologicalstudy
AT blahamichaelj onlinesearchesforsglt2inhibitorsandglp1receptoragonistscorrelatewithprescriptionratesintheunitedstatesaninfodemiologicalstudy